Pneumagen is developing glycan targeted carbohydrate binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer.

Latest news

Aug 28, 2019
Pneumagen Appoints Scientific Advisory Board
Sep 10, 2019
Pneumagen Demonstrates Preclinical Proof-of-Concept for Neumifilâ„¢ in Respiratory Syncytial Virus Infections
Oct 15, 2019
Pneumagen Demonstrates Preclinical Proof-of-Concept in Oncology for Neumonco, a Novel Carbohydrate Binding Module

Meet the team